[144] Fulgent Genetics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for Fulgent Genetics, Inc. (FLGT) reports a proposed sale of 1,063 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $23,414.42, listed for sale on NASDAQ and an approximate sale date of 09/03/2025. The shares were acquired by the seller as restricted stock that vested on 02/28/2022 and were granted as equity compensation for services rendered. The filer also reports two recent sales in August 2025 totaling 1,491 shares for gross proceeds of $32,042.96. The filing includes the seller's representation that they are unaware of any undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Insiders disclosed small, routine sales; transactions represent an orderly disposition of vested equity, not a material shift in ownership.

The Form 144 notifies the market of a planned brokered sale of 1,063 shares valued at $23,414.42 and confirms that those shares originated from a 02/28/2022 restricted stock vesting event tied to equity compensation. Two earlier August 2025 sales totaling 1,491 shares and $32,042.96 in proceeds are reported, indicating prior partial dispositions. Relative to the issuer's stated shares outstanding (30,609,044), the amounts are immaterial from a dilution or control perspective. The filing follows Rule 144 disclosure requirements and contains the standard representation regarding material nonpublic information.

Corporate Governance Expert

TL;DR: Disclosure aligns with governance best practices; sale size is small and appears routine for equity-compensated holders.

The document shows compliance with Rule 144 by disclosing acquisition details, nature of payment (equity compensation), broker information, and recent sales history. The seller affirms no undisclosed material adverse information, which is a required attestation. Because the reported transactions are modest relative to the company's >30 million shares outstanding, they do not by themselves indicate governance concerns or significant insider exit behavior.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004	1063	23414.42	30609044	09/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/28/2022	Restricted stock vest	Fulgent Genetics, Inc.			32000	02/28/2022	Equity compensation for services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Hanlin Gao C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	08/25/2025	548	11782.85
Hanlin Gao C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	08/27/2025	943	20260.11

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for FLGT disclose?

It discloses a proposed brokered sale of 1,063 shares of common stock valued at $23,414.42, to be sold via Morgan Stanley Smith Barney on NASDAQ around 09/03/2025.

How were the shares being sold by the filer acquired?

The shares were acquired on 02/28/2022 as restricted stock that vested and were granted as equity compensation for services rendered by Fulgent Genetics, Inc.

Has the filer sold other FLGT shares recently?

Yes. The filer reported two August 2025 sales: 548 shares on 08/25/2025 for $11,782.85 and 943 shares on 08/27/2025 for $20,260.11, totaling 1,491 shares and $32,042.96.

How large are these sales relative to outstanding shares?

They are immaterial. The filing lists 30,609,044 shares outstanding; the proposed 1,063-share sale is a very small fraction of that total.

Who is the broker handling the sale?

Morgan Stanley Smith Barney LLC (1 New York Plaza, 38th FL, New York, NY 10004) is identified as the broker.